​

Contact SILREAL – Strategic Healthcare & Life Sciences Consulting

​

At SILREAL, we advise healthcare, pharma, biotech, medtech, and digital health companies on policy-driven market access, cross-border strategy, and regulatory execution across Europe, the United States, and China.

Our clients engage us when policy, regulation, and geopolitics directly shape commercial outcomes – from reimbursement and procurement to licensing, localization, and strategic partnerships.

If you are facing complex market entry decisions, regulatory uncertainty, or government-facing strategy in healthcare, SILREAL acts as a decision enabler and risk filter for senior leadership teams.

When to Contact SILREAL

You should contact SILREAL if you are:

• A pharma or biotech company planning market entry or expansion into China or Europe

• A medtech or digital health firm navigating regulatory, reimbursement, or compliance frameworks

• An investor, private equity fund, or corporate venture unit evaluating healthcare assets with policy or regulatory risk

• A government, public institution, or industry association seeking structured dialogue with international healthcare stakeholders

Typical mandates include:

• China market access strategy (pharma, medtech, digital health)

• Policy & government affairs positioning (EU, Germany, China, US)

• Regulatory pathway analysis (NMPA, EU HTA, reimbursement systems)

• Partner search and due diligence (CDMO, CRO, distributors, hospitals)

• Cross-border licensing and localization strategy

• Digital health and AI policy positioning (Germany & China)

• Healthcare investment and market intelligence

How We Work

SILREAL operates as a strategic advisory partner, not a generic consultancy.

We combine:

• Policy intelligence

• Regulatory expertise

• Government and institutional networks

• Commercial strategy execution

Our work typically starts with a paid strategic diagnostic, followed by either:

• A 90-day roadmap project, or

• A long-term retainer mandate (annual advisory engagement)

This structure ensures:

• Clear scope and decision outputs

• Senior-level engagement

• Direct link between policy analysis and commercial action

What Makes SILREAL Different

Unlike traditional consultancies or market research firms, SILREAL focuses on the intersection of policy, regulation, and market access in healthcare.

We specialize in situations where:

• Regulation determines whether a product can be sold at all

• Policy shapes pricing, reimbursement, or procurement

• Government stakeholders influence market structure

• Cross-border data, IP, or localization rules impact scalability

Our positioning is particularly strong in:

• EU ↔ China healthcare strategy

• Germany healthcare policy and digital health

• Pharma and biotech international expansion

• Healthtech and AI regulatory environments

Who We Typically Work With

Our clients include:

• Global pharma and biotech companies

• European and US medtech firms entering China

• Digital health and AI health startups

• Corporate strategy and BD teams

• Private equity and healthcare investors

• Public institutions and policy platforms

Engagements are usually led at:

• C-level (CEO, CFO, CSO)

• VP / Director level (Strategy, Market Access, BD, Regulatory Affairs)

Start a Strategic Conversation

To ensure relevance and efficiency, we prioritize inquiries from organizations that:

• Operate in healthcare or life sciences

• Have cross-border strategic questions

• Are evaluating regulatory, policy, or market access decisions

• Seek senior-level advisory support

Initial conversations are used to assess:

• Strategic context

• Regulatory complexity

• Commercial relevance

• Fit for advisory engagement

If aligned, we will propose a structured paid entry engagement.​